<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>KFF Health News</provider_name><provider_url>https://kffhealthnews.org</provider_url><author_name>brilabuskes</author_name><author_url>https://kffhealthnews.org/news/author/brilabuskes/</author_url><title>Average Consumer Unlikely To Get Any Benefit From Pfizer's Decision To Roll Back Steep Drug Increases - KFF Health News</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="xujTYfL82V"&gt;&lt;a href="https://kffhealthnews.org/morning-breakout/average-consumer-unlikely-to-get-any-benefit-from-pfizers-decision-to-roll-back-steep-drug-increases/"&gt;Average Consumer Unlikely To Get Any Benefit From Pfizer&#x2019;s Decision To Roll Back Steep Drug Increases&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://kffhealthnews.org/morning-breakout/average-consumer-unlikely-to-get-any-benefit-from-pfizers-decision-to-roll-back-steep-drug-increases/embed/#?secret=xujTYfL82V" width="600" height="338" title="&#x201C;Average Consumer Unlikely To Get Any Benefit From Pfizer&#x2019;s Decision To Roll Back Steep Drug Increases&#x201D; &#x2014; KFF Health News" data-secret="xujTYfL82V" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>The company won glowing praise from the White House after it decided to delay its price hikes, but experts say the move is not going to make a big difference to any of the players involved -- including the consumers. Meanwhile, congressional Democrats want more information on the deal between Pfizer and President Donald Trump. And, while the president had success with one company doesn't mean the rest aren't going ahead and raising their prices.</description></oembed>
